08 February 2019 | News
New partner ecosystem enables companies to enhance and expand drug and medical device development initiatives
Clarivate Analytics, a global leader in providing trusted insights and analytics to accelerate the pace of innovation, recently launched a Life Science Alliances Program to provide drug and medical device developers with a new way to significantly advance their research and development (R&D) and commercialization initiatives.
The accredited global program combines Clarivate's solutions with those of world-class technology and service providers to deliver intelligence and actionable insights to biopharmaceutical companies and other researchers around the world.
More than ever, drug and medical device researchers are challenged to quickly and efficiently access, synthesize and analyze data from a growing and increasingly complex array of sources across the development lifecycle. Clarivate's Life Science Alliances Program addresses this challenge by enabling greater collaboration and new capabilities, and already features leading service providers in its growing ecosystem, including:
These enhanced capabilities are enabled by Cortellis Cloud, an integrated, scalable technology platform that host Cortellis, Clarivate's suite of life science intelligence solutions. Through Cortellis Cloud, datapoints from thousands of sources are harmonized within a single unified platform, making it the industry's richest resource for data-driven insights and advanced analytics for Life Science professionals.
The Clarivate Life Science Alliances program will expand to include additional partners in 2019 and beyond.